|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Assessing IGS GPS/Galileo/BDS-2/BDS-3 phase bias products with PRIDE PPP-AR显示文摘Ambiguity Resolution in Precise Point Positioning (PPP-AR) is important to achieving high-precision positioning in wide areas. The International GNSS (Global Navigation Satellite System) Service (IGS) and some other academic organizations have begun to provide phase bias products to enable PPP-AR, such as the integer-clock like products by Centre National d’Etudes Spatials (CNES), Wuhan University (WUM) and the Center for Orbit Determination in Europe (CODE), as well as the Uncalibrated Phase Delay (UPD) products by School of Geodesy and Geomatics (SGG). To evaluate these disparate products, we carry out Global Positioning System (GPS)/Galileo Navigation Satellite System (Galileo) and BeiDou Navigation Satellite System (BDS-only) PPP-AR using 30 days of data in 2019. In general, over 70% and 80% of GPS and Galileo ambiguity residuals after wide-lane phase bias corrections fall in ± 0.1 cycles, in contrast to less than 50% for BeiDou Navigation Satellite (Regional) System (BDS-2);moreover, around 90% of GPS/Galileo narrow-lane ambiguity residuals are within ± 0.1 cycles, while the percentage drops to about 55% in the case of BDS products. GPS/Galileo daily PPP-AR can usually achieve a positioning precision of 2, 2 and 6 mm for the east, north and up components, respectively, for all phase bias products except those based on German Research Centre for Geosciences (GBM) rapid satellite orbits and clocks. Due to the insufficient number of BDS satellites during 2019, the BDS phase bias products perform worse than the GPS/Galileo products in terms of ambiguity fixing rates and daily positioning precisions. BDS-2 daily positions can only reach a precision of about 10 mm in the horizontal and 20 mm in the vertical components, which can be slightly improved after PPP-AR. However, for the year of 2020, BDS-2/BDS-3 (BDS-3 Navigation Satellite System) PPP-AR achieves about 50% better precisions for all three coordinate components. | Jianghui Geng Songfeng Yang Jiang Guo | 2021 | Satellite Navigation2021，2，1： | 3 |
| 2 | Proper animal experimental designs for preclinical research of biomaterials for intervertebral disc regeneration显示文摘Low back pain is a vital musculoskeletal disease that impairs life quality,leads to disability and imposes heavy economic burden on the society,while it is greatly attributed to intervertebral disc degeneration(IDD).However,the existing treatments,such as medicines,chiropractic adjustments and surgery,cannot achieve ideal disc regeneration.Therefore,advanced bioactive therapies are implemented,including stem cells delivery,bioreagents administration,and implantation of biomaterials etc.Among these researches,few reported unsatisfying regenerative outcomes.However,these advanced therapies have barely achieved successful clinical translation.The main reason for the inconsistency between satisfying preclinical results and poor clinical translation may largely rely on the animal models that cannot actually simulate the human disc degeneration.The inappropriate animal model also leads to difficulties in comparing the efficacies among biomaterials in different reaches.Therefore,animal models that better simulate the clinical charateristics of human IDD should be acknowledged.In addition,in vivo regenerative outcomes should be carefully evaluated to obtain robust results.Nevertheless,many researches neglect certain critical characteristics,such as adhesive properties for biomaterials blocking annulus fibrosus defects and hyperalgesia that is closely related to the clinical manifestations,e.g,low back pain.Herein,in this review,we summarized the animal models established for IDD,and highlighted the proper models and parameters that may result in acknowledged IDD models.Then,we discussed the existing biomaterials for disc regeneration and the characteristics that should be considered for regenerating different parts of discs.Finally,well-established assays and parameters for in vivo disc regeneration are explored. | Yizhong Peng Xiangcheng Qing Hongyang Shu Shuo Tian Wenbo Yang Songfeng Chen Hui Lin Xiao Lv Lei Zhao Xi Chen Feifei Pu Donghua Huang Xu Cao Zengwu Shao | 2021 | Biomaterials Translational2021，2，2： | 2 |
| 3 | Neoadjuvant chemotherapy with pingyangmycin can inhibit the amplification and metastasis of laryngeal squamous cell carcinoma显示文摘Objective:To evaluate the short-term effects of neoadjuvant chemotherapy with pingyangmycin(PYM)in the treat-ment of laryngeal squamous cell carcinoma.Methods:24 cases of laryngeal squamous cell carcinoma were treated with PYM before the operation,and the surgeries were undergone within one week after neoadjuvant chemotherapy.PCNA,p53,Bcl-2 and CD44v6 were detected in the specimens of tumor,retreated tumor and normal tissue using immunohistochemical methods.Results:Apoptosis could be detected more often in specimens with tumor and retreated tumor after chemotherapy than that before.The expression of PCNA,p53,Bcl-2 and CD44v6 in tumor tissue after neoadjuvant chemotherapy with PYM was weaker than that before the chemotherapy.There was significant difference in the positive ratio of PCNA,p53,Bcl-2 and CD44v6 be-tween retreated tumor and tumor.Conclusion:After neoadjuvant chemotherapy with PYM,a large number of tumor cells died.The amplification and metastasis of tumor were suppressed by neoadjuvant chemotherapy with PYM. | Xiaolong Li Ming Gao Haifeng Yu Benyi Xu Zhengjin Ge Yang Yu Songfeng Wei Shuling Li | 2006 | The Chinese-German Journal of Clinical Oncology2006，5，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员